Novartis MS Drug Patent Ruled Invalid

Apr 13, 2017

A federal appeals court held that Novartis’ patent on the blockbuster multiple sclerosis drug Gilenya was invalid, according to a Reuters article.

The U.S. Circuit Court of Appeals for the Federal Circuit affirmed a 2015 ruling by the U.S. Patent Trial and Appeal Board, which agreed with generic drug manufacturers Torrent Pharmaceuticals, Apotex and Mylan Pharmaceuticals that the Gilenya patent was obvious, the story said.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments